Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma
Clinical trial NCT04729959 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04729959
- Sponsor
- National Cancer Institute (NCI)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-11
- Primary completion
- 2025-06-15
- Enrollment
- 61
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.